Perrigo Co. (PRGO) said Tuesday it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to Vanos® Cream 0.1%.
Perrigo said it was awarded 180-days of generic drug exclusivity. Perrigo had previously resolved litigation with the brand and has commenced shipment of the product.
Vanos® Cream 0.1% (fluocinonide cream 0.1%) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older and has estimated annual sales of about $107 million.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.